Wanbury Ltd, a Mumbai based Rs 100-crore plus pharma company, reported satisfactory performance during the first quarter ended June 2006. Its net sales moved up by 41 per cent to Rs 27.38 crore from Rs 19.43 crore in the corresponding period of last year. The net profit, however, improved marginally to Rs 3.10 crore from Rs 3.01 crore. The company's equity capital increased to Rs 12.75 crore from Rs 9.49 crore. After considering the rise in the equity capital, its earning per share worked out to Rs 2.43 as compared to Rs 3.18 in the last period.
The company has utilized Rs 37.25 crore out of the GDR issue of Rs 44.02 crore. The company has set up two R&D centres and expanded its Metformin capacity during 2005-06. It acquired 51 per cent stake in Doctors Organic Chemicals for a consideration of Rs 37 crore. DOCL has a US FDA approved facility and presently sells active pharmaceutical ingredients in regulated market like the US, Europe and few other overseas markets.
Wanbury's net sales for the year ended March 2006 increased to Rs 108.84 crore from Rs 72.27 crore and it earned a net profit of Rs 10.73 crore from Rs 7.01 crore.